Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16924883 | 0.76 | LMNA (0.50) | LMNATSHRNPSR1ALDH1A1MEN1 | |
| SCHEMBL11785775 | 0.74 | CRBN (0.32) | CRBN | |
| SCHEMBL15658755 | 0.73 | LMNA (0.43) | LMNATSHRNPSR1KDM4ECYP2C19 | |
| SCHEMBL15659217 | 0.69 | LMNA (0.40) | LMNACRBNTSHRNPSR1KDM4E | |
| SCHEMBL7973289 | 0.67 | LMNA (0.45) | LMNATSHRNPSR1ALDH1A1MEN1 | |
| SCHEMBL31509083 | 0.65 | LMNA (0.78) | LMNATSHRNPSR1ALDH1A1MEN1 | |
| SCHEMBL1605832 | 0.64 | AR (0.36) | LMNATSHRNPSR1MEN1CYP1A2 | |
| SCHEMBL19474905 | 0.64 | LMNA (0.36) | LMNA | |
| SCHEMBL21161955 | 0.63 | POLB (0.30) | CRBNPOLB | |
| Methyprylon SCHEMBL155839 | 0.63 | LMNA (0.40) | LMNATSHRNPSR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 560 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | claimed |
| EP-4041726-B1 | PROCESS FOR THE PRODUCTION OF 5-(4-((2 S,5 S)-5-(4-CHLOROBENZYL)-2-METHYLMORPHOLINO)PIPERIDIN-1-YL)-1 H-1,2,4-TRIAZOL-3-AMINE | MOLECURE SA (PL) | 2025-09-17 | — | — | EP | claimed |
| US-12408625-B2 | Food bowl kit | MARS, INCORPORATED (US) | 2025-09-09 | — | — | US | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| EP-4593631-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | Mars, Incorporated (US) | 2025-08-06 | — | — | EP | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| EP-4510999-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | Bristol-Myers Squibb Company (US) | 2025-02-26 | — | — | EP | claimed |
| US-20240224934-A9 | FOOD BOWL KIT | MARS, INCORPORATED (US) | 2024-07-11 | — | — | US | claimed |
| US-20240165020-A1 | LIQUISOFT CAPSULES | PATHEON SOFTGELS INC (US) | 2024-05-23 | — | — | US | claimed |
| EP-4360653-A2 | LIQUISOFT CAPSULES | Patheon Softgels Inc. (US) | 2024-05-01 | — | — | EP | claimed |
| WO-2009018280-A2 | SUBSTITUTED INDOLES | AUSPEX PHARAMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| EP-1651184-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS | Warner-Lambert Company LLC (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2004096174-A1 | FAST DISSOLVING ORALLY CONSUMABLE FILMS CONTAINING PHARMACEUTICALLY ACTIVE AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2004-11-11 | — | — | WO | claimed |
| US-20030206942-A1 | Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent | MCNEIL-PPC, INC | 2003-11-06 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0552360-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-07-28 | — | — | EP | claimed |
| WO-1993003825-A1 | A COMPOSITION AND METHOD FOR SIMULTANEOUS ABSORPTION OF SULFUR DIOXIDE AND NITRIC OXIDE | THE DOW CHEMICAL COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| US-5167941-A | Sulfur dioxide; cationic polyelectrolyte stabilizers | THE DOW CHEMICAL COMPANY (US) | 1992-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | LMNA 1459/4885CRBN 1774/4885TSHR 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.